All In Biotech

Drug Trial Radar · NCT03811535

A Research Study in Children With a Low Level of Hormone to Grow. Treatment is Somapacitan Once a Week Compared to Norditropin® Once a Day (REAL4)

A Trial Comparing the Effect and Safety of Once Weekly Dosing of Somapacitan With Daily Norditropin® in Children With Growth Hormone Deficiency

Last checked: Nov 20, 2026Latest source record: Oct 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 200 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

200

Actual

Start

May 20, 2019

Primary completion

Nov 10, 2021

Study completion Sep 30, 2025

Sponsor

Lead sponsor
Novo Nordisk A/SNovo Nordisk (NVO)
Sponsor type
Industry
First posted
Jan 22, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, up to 11 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study compares 2 medicines for children who do not have enough hormone to grow: somapacitan given once a week (a new medicine) and Norditropin® given once a day (the medicine doctors can already prescribe). Researchers will test to see how well somapacitan works. The study will also test if somapacitan is safe. Participants will either get somapacitan or Norditropin® - which treatment participants get, is decided by chance. Both participants and the study doctor will know which treatment participants get. The study will last for 4 years. Participants will attend 19 clinic visits and have 1 phone call with the study doctor.

Conditions

  • Growth Hormone Deficiency in Children

Interventions

  • SomapacitanDrug

    Somapacitan will be administered subcutaneously (s.c.; under the skin) once weekly by PDS290 pen-injector. Somapacitan can be injected any time during the once weekly dosing day. The dose will be calculated based on the subject's current body weight.

  • Norditropin®Drug

    Norditropin® will be administered s.c. once daily by FlexPro® pen-injector. Norditropin® should be injected daily in the evening. The dose will be calculated based on the subject's current body weight.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Height Velocity: In-trial Observation PeriodTime frame: From baseline (week 0) to visit 7 (week 52)
  2. Height Velocity: On-treatment Observation PeriodTime frame: From baseline (week 0) to visit 7 (week 52)

Locations

139 sites in 26 countries. Site status is shown where the registry gives one.

  • Univ of AL at Birmingham_BRM

    Birmingham, Alabama

  • Children's Hospital Los Angeles - Endocrinology

    Los Angeles, California

  • Valley Children's Hospital

    Madera, California

  • Children's Hosp Of Orange

    Orange, California

  • Sutter Valley Med Fdt Ped Endo

    Sacramento, California

  • Rocky Mt Ped and Endo

    Centennial, Colorado

  • Ped Endo Assoc PC-G.V

    Greenwood Village, Colorado

  • Yale-New Haven Hospital

    New Haven, Connecticut

  • A.I. duPont Hospital for Children/Nemours

    Wilmington, Delaware

  • Pediatric Endocrine & Wellness Center

    Aventura, Florida

  • Van Meter Pediatric Endo PC

    Atlanta, Georgia

  • Riley Hospital For Children

    Indianapolis, Indiana

  • University OF Iowa

    Iowa City, Iowa

  • Univ of Minnesota M.C.H.

    Minneapolis, Minnesota

  • Children's Minnesota

    Saint Paul, Minnesota

  • Children's Mercy Clinics

    Kansas City, Missouri

  • The Docs

    Las Vegas, Nevada

  • Goryeb Children's Hospital

    Morristown, New Jersey

  • UBMD Peds-Div of Endo/Diabetes

    Buffalo, New York

  • NYU Langone Hospital-LI

    Mineola, New York

  • WakeMed Childn Endo-Dbt_Raleig

    Raleigh, North Carolina

  • CCHMC_Cinc

    Cincinnati, Ohio

  • Univ Oklahoma Sci Ctr OK City

    Oklahoma City, Oklahoma

  • UPMC Child Hosp-Pittsburgh

    Pittsburgh, Pennsylvania

  • Dell Children's Medical Center

    Austin, Texas

  • Cook Children's Medical Center

    Fort Worth, Texas

  • MultiCare Inst for Res & Innov

    Tacoma, Washington

  • CHU Bab El Oued Pediatrics Dept

    Algiers, Algeria

  • Endo and Diab Dept El Oued

    Algiers, Algeria

  • endocrino-diabetology department, Hospital IBN BADIS.

    Constantine, Algeria

  • Med. Univ. Graz -Klinische Abteilung f. Allgemeine Pädiatrie

    Graz, Austria

  • LKH Salzburg- Univ. Klinik f. Kinder- und Jugendheilkunde

    Salzburg, Austria

  • LKH St. Poelten, Kinder-und Jugendheilkunde

    Sankt Pölten, Austria

  • Salzkammergut-Klinikum Vöcklabruck

    Vöcklabruck, Austria

  • Stollery Children's Hospital

    Edmonton, Alberta, Canada

  • Mntrl Chldrn Hsptl PedEndoMUHC

    Montreal, Quebec, Canada

  • Rigshospitalet Klinik for Vækst og Reproduktion Afsnit 5064

    Copenhagen Ø, Denmark

  • Tallinn Children's Hospital

    Tallinn, Estonia

  • Tartu University Hospital Children's Clinic

    Tartu, Estonia

  • Centre Hospitalier Universitaire D'Angers-2

    Angers, France

Showing 40 of 139 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.